NYB Partners with Nvidia, HP and Equinix to Build Largest AI Drug Discovery Library

Nanyang Biologics, a Singapore-based company, has partnered with Nvidia, HP, and Equinix to build the world's largest natural compound library for AI drug discovery. NYB is entering into a business combination agreement with RF Acquisition Corp II, a publicly traded special purpose acquisition company, to become a publicly listed company on Nasdaq. The transaction gives NYB approximately $1.5 billion in pre-transaction equity value. NYB's existing shareholders, including The9, will roll over 100% of the equity and retain a majority of the combined company's outstanding shares.

Nanyang Biologics (NYB), a Singapore-based company, has announced plans to go public on Nasdaq through a business combination with RF Acquisition Corp II (RFAI), a publicly traded special purpose acquisition company. The transaction, valued at approximately $1.5 billion, aims to accelerate NYB's AI-driven drug discovery efforts and position it as a leading player in the global biotechnology sector.

NYB, which is backed by The9 Limited, has partnered with Nvidia, HP, and Equinix to build the world's largest natural compound library for AI drug discovery. The collaboration involves developing scalable AI platforms and creating secure, enterprise-grade infrastructure for healthcare innovation. This initiative positions Singapore as a global hub where biodiversity meets artificial intelligence, enabling the discovery of new drug molecules from natural sources.

The business combination with RFAI will result in NYB becoming a publicly listed company, with the combined entity expected to be listed on Nasdaq under the reserved ticker symbol "NYB". Existing shareholders, including The9, will roll over 100% of the equity and retain a majority of the combined company's outstanding shares. The transaction has been approved by the boards of directors of NYB and RFAI and is expected to close in the first or second quarter of 2026, subject to shareholders' approval and the satisfaction of customary closing conditions.

NYB's mission is to turn hidden chemistry into therapies and wellness solutions by leveraging its proprietary AI platform, which maps vast biochemical spaces into feasible drug candidates. The company's pipeline includes five molecules targeting high unmet needs in oncology, cardiovascular, and mental health, with NB-A002 being a first-in-class oncology therapy addressing DNA Damage Response (DDR) cancers.

The public listing will enable NYB to accelerate its drug discovery process, reduce R&D time and costs, and open new opportunities for humanity to pursue longevity. The company's Chairman, Dr. Roland Ong, commented on the plan, stating that public listing will break through barriers that have long hindered the advancement of medicine.